Who Paid My Doc
Pamela Matthews
Registered Nurse, Psychiatric/Mental Health, Adult Bourne, MA Nurse Practitioner
NPI 1558852301 CMS profile 10984703
243 Main St Ste 1, Bourne, MA 02532
General payments
$2,912
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Pamela Matthews of Bourne, MA is reported in the CMS Open Payments database as having received $2,912 across 162 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 94th percentile of Registered Nurse, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $249 | 9 | |
| 2024 | General | $282 | 17 | |
| 2023 | General | $480 | 31 | |
| 2022 | General | $493 | 22 | |
| 2021 | General | $1,408 | 83 |
Beside peers
- Pamela Matthews
- Registered Nurse, Psychiatric/Mental Health, Adult median
- Middle half of Registered Nurse, Psychiatric/Mental Health, Adult
- National median
In program year 2025, general payments to Pamela Matthews were reported at $249. Among 96 Registered Nurse, Psychiatric/Mental Health, Adult profiles paid that year, the median was $121 and the middle half received between $39 and $265.
Show as a table
| Year | Pamela Matthews | Registered Nurse, Psychiatric/Mental Health, Adult median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $1,408 | $108 | $31–$328 | $132 |
| 2022 | $493 | $99 | $22–$306 | $149 |
| 2023 | $480 | $99 | $43–$313 | $160 |
| 2024 | $282 | $119 | $30–$319 | $164 |
| 2025 | $249 | $121 | $39–$265 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
206
Drug cost
$377,327
Branded share of claims
50.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Austedo Xr Deutetrabenazine | Brand | 44 | $284,400 | |
| Austedo Deutetrabenazine | Brand | 14 | $70,279 | |
| Vraylar Cariprazine Hcl | Brand | 12 | $20,116 | |
| Perphenazine | Generic | 14 | $969 | |
| Venlafaxine Hcl Er Venlafaxine Hcl | Brand | 22 | $751 | |
| Bupropion Xl Bupropion Hcl | Brand | 12 | $327 | |
| Clonazepam | Generic | 25 | $146 | |
| Trazodone Hcl | Generic | 12 | $117 | |
| Lamotrigine | Generic | 12 | $76 | |
| Zolpidem Tartrate | Generic | 13 | $70 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.
Payments and prescribing
4 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| VRAYLAR |
|
$183 | 12 | — |
| INVEGA SUSTENNA |
|
$37 | — | — |
| REXULTI |
|
$26 | — | — |
| UZEDY |
|
$17 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
162 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Registered Nurse, Psychiatric/Mental Health, Adult in Massachusetts
Maria Grotz
Registered Nurse, Psychiatric/Mental Health, Adult · Orleans, MA
Donna Principato Sawyer
Registered Nurse, Psychiatric/Mental Health, Adult · Milton, MA
Elizabeth Soccorso
Registered Nurse, Psychiatric/Mental Health, Adult · Beverly, MA
Constance Clarke
Registered Nurse, Psychiatric/Mental Health, Adult · Braintree, MA
Christopher Footit
Registered Nurse, Psychiatric/Mental Health, Adult · Hadley, MA
Catherine Toro-McCue
Registered Nurse, Psychiatric/Mental Health, Adult · Boston, MA
Related records
Registered Nurse, Psychiatric/Mental Health, Adult in Massachusetts
Practitioners in the same specialty and state, ranked by reported value.
All Registered Nurse, Psychiatric/Mental Health, Adult
Everyone recorded under this specialty, nationwide.
Doctors in Massachusetts
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.